RxDoctor Payments Data

Christian Romero

Family · El Centro, CANPI 1942806237

Payments from drug & device makers

$1,435in general payments, 2019–2025

Across 65 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$255
  • AstraZeneca$236
  • Novo Nordisk$173
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$160
  • Boehringer Ingelheim$79
  • GSK$65
  • plus $468 from 16 others

What the payments were for

  • Food & beverage$1,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,435 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol120$100,479
OzempicSemaglutide105$97,686
JanuviaSitagliptin Phosphate55$59,026
LinzessLinaclotide68$56,729
EntrestoSacubitril/Valsartan49$52,865
EliquisApixaban30$42,938
JardianceEmpagliflozin43$40,040
RybelsusSemaglutide30$37,211
TrulicityDulaglutide30$31,026
DapagliflozinDapagliflozin Propanediol45$28,995
ProliaDenosumab15$24,450
KerendiaFinerenone34$22,052
TradjentaLinagliptin29$20,793
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$16,718
XareltoRivaroxaban23$13,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$173$134,897135 claims
AstraZenecaFarxiga$236$100,479120 claims
Boehringer IngelheimJardiance, Tradjenta$79$60,83372 claims
AbbVieLinzess$26$56,72968 claims
PfizerEliquis$49$42,93830 claims
Lilly USA, LLCTrulicity$15$31,02630 claims
AmgenProlia$40$24,45015 claims
BayerKerendia$59$22,05234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →